Hormone therapy plus current treatments improves survival in prostate cancer
March 23rd 2023Darolutamide increased overall survival compared to placebo in the overall patient population and patients with high-volume, high-risk mHSPC as well as in patients with low-risk metastatic hormone-sensitive prostate cancer.
Study highlights how DTC online platforms often fail to convey risks of testosterone therapy
December 8th 2022“While there’s benefit in improving access, there’s also potential for harm when providers fail to follow evidence-based guidelines, or when the benefits and risks of treatment are not appropriately communicated," said Joshua A. Halpern, MD.